Self-Service Login / Register | bluecrossnepastore.com
Powered by Google
Open Enrollment Ended March 31st. If you have a qualifying life event, you may still be able to buy coverage for 2014. Call us today at 1.866.514.2454. Learn More

February 2013

Adjust type sizesmallmediumlarge

Genetic Testing
Genetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes

Genetic testing for MMR gene mutations is considered medically necessary in the following patients:

  • Patients with endometrial cancer and one first-degree relative diagnosed with a Lynch-associated cancer, for the diagnosis of Lynch syndrome
  • CRC diagnosed with one or more first-degree relatives with an HNPCC-related tumor (colorectal, endometrial, stomach, ovarian, pancreas, bladder, ureter and renal pelvis, biliary tract, brain [usually glioblastoma as seen in Turcot syndrome], sebaceous bland adenomas and keratoacanthomas in Muir-Torre syndrome, and carcinoma of the small bowel), with one of the cancers being diagnosed at younger than age 50 years, OR CRC diagnosed in 2 or more first- or second-degree relatives with HNPCC-related tumor, regardless of age.

Experimental/Investigative Services Pathology/Laboratory
Proteomics-based Testing for the Evaluation of Ovarian (Adnexal) Masses

No coverage will be provided for all uses of the proteomics-based OVA1 and ROMA tests, including but not limited to the following as they are considered investigational:

  1. Preoperative evaluation of adnexal masses to triage for malignancy; or
  2. Screening for ovarian cancer; or
  3. Selecting patients for surgery for an adnexal mass; or
  4. Evaluation of patients with clinical or radiologic evidence of malignancy; or
  5. Evaluation of patients with nonspecific signs or symptoms suggesting possible malignancy; or
  6. Post-operative testing and monitoring to assess surgical outcome and/or to detect recurrent malignant disease following treatment.